In this large population-based cohort study including 4753 adult patients with breast cancer, tamoxifen combined with a DOAC was not associated with a higher risk of major hemorrhage requiring an emergency department visit or hospitalization compared with the combination of an aromatase inhibitor and a DOAC. The gene discussed is CYP19A1; the disease is breast cancer.